Literature DB >> 11748305

Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1.

C Eng1, L C Brody, T M Wagner, P Devilee, J Vijg, C Szabo, S V Tavtigian, K L Nathanson, E Ostrander, T S Frank.   

Abstract

While sequence analysis is considered by many to be the most sensitive method of detecting unknown mutations in large genes such as BRCA1, most published estimates of the prevalence of mutations in this gene have been derived from studies that have used other methods of gene analysis. In order to determine the relative sensitivity of techniques that are widely used in research on BRCA1, a set of blinded samples containing 58 distinct mutations were analysed by four separate laboratories. Each used one of the following methods: single strand conformational polymorphism analysis (SSCP), conformation sensitive gel electrophoresis (CSGE), two dimensional gene scanning (TDGS), and denaturing high performance liquid chromatography (DHPLC). Only the laboratory using DHPLC correctly identified each of the mutations. The laboratory using TDGS correctly identified 91% of the mutations but produced three apparent false positive results. The laboratories using SSCP and CSGE detected abnormal migration for 72% and 76% of the mutations, respectively, but subsequently confirmed and reported only 65% and 60% of mutations, respectively. False negatives therefore resulted not only from failure of the techniques to distinguish wild type from mutant, but also from failure to confirm the mutation by sequence analysis as well as from human errors leading to misreporting of results. These findings characterise sources of error in commonly used methods of mutation detection that should be addressed by laboratories using these methods. Based upon sources of error identified in this comparison, it is likely that mutations in BRCA1 and BRCA2 are more prevalent than some studies have previously reported. The findings of this comparison provide a basis for interpreting studies of mutations in susceptibility genes across many inherited cancer syndromes.

Entities:  

Mesh:

Year:  2001        PMID: 11748305      PMCID: PMC1734796          DOI: 10.1136/jmg.38.12.824

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  29 in total

1.  High detection rate for BRCA2 mutations in male breast cancer families from North West England.

Authors:  D G Evans; M Bulman; K Young; D Gokhale; F Lalloo
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

2.  Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics.

Authors:  M de la Hoya; O Díez; P Pérez-Segura; J Godino; J M Fernández; J Sanz; C Alonso; M Baiget; E Díaz-Rubio; T Caldés
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

3.  Renewable standard reference material for the detection of TP53 mutations.

Authors:  Catherine D O'Connell; Lois A Tully; Joseph M Devaney; Michael A Marino; John P Jakupciak; Donald H Atha
Journal:  Mol Diagn       Date:  2003

4.  BRCA1 variants in a family study of African-American and Latina women.

Authors:  Roberta McKean-Cowdin; Heather Spencer Feigelson; Lucy Y Xia; Celeste Leigh Pearce; Duncan C Thomas; Daniel O Stram; Brian E Henderson
Journal:  Hum Genet       Date:  2005-02-23       Impact factor: 4.132

5.  Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

Authors:  Kathleen E Malone; Colin B Begg; Robert W Haile; Ake Borg; Patrick Concannon; Lina Tellhed; Shanyan Xue; Sharon Teraoka; Leslie Bernstein; Marinela Capanu; Anne S Reiner; Elyn R Riedel; Duncan C Thomas; Lene Mellemkjaer; Charles F Lynch; John D Boice; Hoda Anton-Culver; Jonine L Bernstein
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

6.  Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.

Authors:  Viive M Howell; John W Cardinal; Anne-Louise Richardson; Oliver Gimm; Bruce G Robinson; Deborah J Marsh
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

7.  The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer.

Authors:  Chuan-Gui Song; Zhen Hu; Jiong Wu; Jian-Min Luo; Zhen-Zhou Shen; Wei Huang; Zhi-Ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

8.  A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations.

Authors:  Cristina Martínez-Bouzas; Elena Beristain; Enrique Ojembarrena; Jose Errasti; Karmele Mujika; Noelia Viguera; Maria Isabel Tejada
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

9.  The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.

Authors:  Maurizia Dalla Palma; Susan M Domchek; Jill Stopfer; Julie Erlichman; Jill D Siegfried; Jessica Tigges-Cardwell; Bernard A Mason; Timothy R Rebbeck; Katherine L Nathanson
Journal:  Cancer Res       Date:  2008-08-14       Impact factor: 12.701

10.  Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: a study of familial and early onset cases.

Authors:  Yasmine Kanaan; Elikem Kpenu; Kim Utley; Lucile Adams-Campbell; Georgia M Dunston; Lawrence C Brody; Carolyn Broome
Journal:  Hum Genet       Date:  2003-08-26       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.